J&J Pharma R&D Extends License for OmniViz Software | GenomeWeb

NEW YORK (GenomeWeb News) – Johnson & Johnson Pharmaceutical Research and Development has extended a licensing agreement for BioWisdom’s OmniViz visualization and data-mining software, BioWisdom said today.

BioWisdom merged with OmniViz early last year.

The OmniViz software offers visualization of text, numerical, and categorical data as well as genome sequences, chemical structures, and text files.

Financial terms of the agreement were not released.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.